Teva Pharmaceuticals
TEVA
428 hedge funds and large institutions have $3.74B invested in Teva Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 132 increasing their positions, 137 reducing their positions, and 60 closing their positions.
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
11% more call options, than puts
Call options by funds: $162M | Put options by funds: $145M
4% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 137
2% less funds holding
Funds holding: 438 → 428 (-10)
6.22% less ownership
Funds ownership: 50.44% → 44.22% (-6.2%)
15% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 60
24% less capital invested
Capital invested by funds: $4.95B → $3.74B (-$1.21B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$115M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$104M |
| 3 |
SPC
Slate Path Capital
New York
|
+$101M |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$93.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$63.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$731M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$410M |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$189M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$41.1M |
| 5 |
Citigroup
New York
|
-$32.9M |
TEVA Hedge Fund Activity: Q2 2023 in Review
428 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2023, worth a combined $3.74B — down 24% from $4.95B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of TEVA and 51 opened new positions — a net loss of 9 holders — while 137 trimmed existing stakes and 132 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $115M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $731M sold.
- 428 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2023, down from 438 in Q1 2023.
- Funds reported $3.74B of Teva Pharmaceuticals stock for Q2 2023, down 24% quarter-over-quarter.
- 51 funds opened new Teva Pharmaceuticals positions in Q2 2023 and 60 closed out, a net change of -9 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2023 was Rubric Capital Management (New York), an estimated $115M added.
- The largest Teva Pharmaceuticals seller in Q2 2023 was Capital Research Global Investors, an estimated $731M sold.
Based on aggregated 13F filings for Q2 2023.